REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Director/PDMR Shareholding
01/10/2020 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201001:nRSA6925Aa
RNS Number : 6925A MaxCyte, Inc. 01 October 2020
MaxCyte, Inc.
("MaxCyte" or the "Company")
Director Dealings
Maryland, USA - 1 October 2020: MaxCyte (LSE: MXCT, MXCS), the global
cell-based medicines and life sciences company, announces that J. Stark
Thompson, Non-Executive Chairman of the Company, has exercised options over
25,000 shares of common stock of 0.1 pence of the Company ("Common Stock")
("Exercise"). In order to fund a near term personal tax liability, the 25,000
new shares of Common Stock issued pursuant to the Exercise ("New Common
Stock") have today been sold by Dr Thompson at a price of £3.55 pence per
Common Stock ("Sale"). Dr Thompson has no current intention of making further
sales of MaxCyte shares.
Following the Exercise and Sale, Dr Thompson's holding of Common Stock remains
unchanged at a total of 110,918 Common Stock representing a total of 0.14% of
the issued share capital of the Company. Dr Thompson holds a further
241,333 options over Common Stock.
Total voting rights
The New Common Stock will be allocated out of the common stock the subject of
the block listing announced on 2 May 2017. The New Common Stock will
rank pari passu with the existing shares of common stock of the Company. The
total issued stock capital of the Company following the above will be
77,305,169 shares of common stock. Shareholders in the Company may use this
figure as the denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their interest
in, the stock capital of the Company.
The number of unrestricted shares of Common Stock trading under the symbol
'MXCT' is 67,405,080 and the number of restricted shares of Common Stock
trading under the symbol 'MXCS' is 9,900,089.
This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 ("MAR").
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name J. Stark Thompson
2 Reason for the notification
a) Position/status Non-Executive Chairman and PDMR
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name MaxCyte, Inc.
b) LEI 54930053YHXULRFCU991
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary shares of 0.1 pence each
b) Identification Code US57777K1060
c) Nature of the transaction Exercise of options and Sale of Common Stock by PDMR
d) Price(s) and volume(s) Price(s) Volume(s)
£3.55 25,000
e) Aggregated information N/A (Single Transaction)
- Aggregated volume
- Price
f) Date of the transaction 1.10.20
g) Place of the transaction London Stock Exchange, AIM Market (XLON)
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life sciences
company. As the inventors of the premier cell-engineering enabling technology,
the Company helps bring the promise of next-generation cell and gene-editing
therapies to life. The Company's technology is currently being deployed by
leading drug developers worldwide, including all of the top ten global
biopharmaceutical companies. MaxCyte licences have been granted for more than
120 cell therapy programmes, with more than 90 licensed for clinical use, and
the Company has now entered into eleven clinical/commercial license
partnerships with leading cell therapy and gene editing developers. MaxCyte
was founded in 1998, is listed on the London Stock Exchange (AIM:MXCT, MXCL)
and is headquartered in Gaithersburg, Maryland, US. For more information,
visit www.maxcyte.com (http://www.maxcyte.com/) .
For further information, please contact:
MaxCyte Inc. +1 301 944 1660
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer
Nominated Adviser and Joint Corporate Broker +44 (0)20 7886 2500
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden
Joint Corporate Broker +44 (0)20 7260 1000
Numis Securities Limited
James Black
Duncan Monteith
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHEAENEDEAEEAA